Glembatumumab vedotin

Glembatumumab vedotin
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	GPNMB
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1182215-65-1 (glembatumumab);
ChemSpider	none;
UNII	1568H6A58U;
KEGG	D09912 ;
	(what is this?) (verify)

Glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

In May 2010, the U.S FDA granted Fast Track designation to CDX-011 for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer.^[1]

^ "Celldex Therapeutics Announces Initiation Of Randomized Phase 2b Clinical Trial Of CDX-011 In Advanced Breast Cancer". 22 Sep 2010. Archived from the original on 4 November 2010. Retrieved 8 November 2010.

[1] "Celldex Therapeutics Announces Initiation Of Randomized Phase 2b Clinical Trial Of CDX-011 In Advanced Breast Cancer". 22 Sep 2010. Archived from the original on 4 November 2010. Retrieved 8 November 2010.

[1]